These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30686952)

  • 1. A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults.
    Lee J; Choi JH; Wie SH; Park SH; Choi SM; Lee MS; Kim TH; Lee HJ; Kang JH
    J Korean Med Sci; 2019 Jan; 34(4):e31. PubMed ID: 30686952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of immunogenicity and safety of the new tetanus-reduced diphtheria (Td) vaccines (GC1107) in healthy Korean adolescents: a phase II, double-blind, randomized, multicenter clinical trial.
    Rhim JW; Lee KY; Kim SY; Kim JH; Kim HH; Kim HM; Choi YY; Ma SH; Kim DH; Ahn DH; Kang JH
    J Korean Med Sci; 2013 Apr; 28(4):586-92. PubMed ID: 23579367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
    Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
    JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
    Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
    Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the new reduced-dose tetanus-diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study.
    Han SB; Rhim JW; Shin HJ; Kim SY; Kim JH; Kim HH; Lee KY; Kim HM; Choi YY; Ma SH; Kim CS; Kim DH; Ahn DH; Kang JH
    J Microbiol Immunol Infect; 2017 Apr; 50(2):207-213. PubMed ID: 26055693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a single intramuscular dose of a diphtheria-tetanus toxoid (Td) vaccine (GC1107) in Korean adults.
    Lee S; Park WB; Shin KH; Ahn DH; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Vaccine; 2011 Oct; 29(44):7638-43. PubMed ID: 21864613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of a Newly Developed Tetanus-Diphtheria Toxoid (Td) in Healthy Korean Adolescents: a Multi-center, Randomized, Double-blind, Active-Controlled Phase 3 Trial.
    Choi UY; Kim KH; Lee J; Eun BW; Kim HM; Lee KY; Kim DH; Ma SH; Lee J; Kim JH
    J Korean Med Sci; 2021 Dec; 36(49):e313. PubMed ID: 34931494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
    Embree J; Law B; Voloshen T; Tomovici A
    Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response.
    Halperin SA; Langley JM; Ye L; MacKinnon-Cameron D; Elsherif M; Allen VM; Smith B; Halperin BA; McNeil SA; Vanderkooi OG; Dwinnell S; Wilson RD; Tapiero B; Boucher M; Le Saux N; Gruslin A; Vaudry W; Chandra S; Dobson S; Money D
    Clin Infect Dis; 2018 Sep; 67(7):1063-1071. PubMed ID: 30010773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL
    Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.